Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T04:47:19.561Z Has data issue: false hasContentIssue false
  • English
  • Français

Costing Methods in the Canadian Literature on the Economic Evaluation of Health Care: A Survey and Assessment

Published online by Cambridge University Press:  10 March 2009

Philip Jacobs  and
John Bachynsky
Philip Jacobs
Affiliation:
University of Alberta
John Bachynsky
Affiliation:
University of Alberta
Get access Rights & Permissions [Opens in a new window]

Abstract

We reviewed the Canadian literature on cost-effectiveness from 1980–1995 with regard to costing methodologies. We abstracted each study using a list of data elements that describe costing methodology, and evaluated costing methodologies in the light of biases in costing methods, site, and case-mix selection.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 12 , Issue 4 , Fall 1996 , pp. 721 - 734
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Allen, U. D., Read, S., & Gafni, A.Zidovudine for chemoprophylaxis after occupational exposure to HIV-infected blood: An economic evaluation. Clinical Infectious Diseases, 1992, 14, 822–30.Google Scholar
2.Anderson, D. R., O'Brien, B. J., Levine, M. N., et al. Efficacy and cost of low-molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Annals of Internal Medicine, 1993, 119, 1105–12.Google Scholar
3.Australia Commonwealth Department of Health, Housing, and Community Services. Manual of resource items and their associated costs. Canberra: Commonwealth Department, 1992.Google Scholar
4.Barrett, B. J., Parfrey, P. S., Foley, R. N., & Detsky, A. S.An economic analysis of strategies for the use of contrast media for diagnostic cardiac catheterization. Medical Decision Making, 1994, 14, 325–35.Google Scholar
5.Baskett, T. F., & Parsons, M. L.Prevention of Rh(D) alloimmunization: A cost-benefit analysis. Canadian Medical Association Journal, 1990, 142, 337–39.Google Scholar
6.Boyle, M. H., Torrance, G. W., Sinclair, J. C., & Horwood, S. P.Economic evaluation of neonatal intensive care of very-low-birth-weight infants. New England Journal of Medicine, 1983, 308, 1330–37.Google Scholar
7.Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of Pharmaceuticals: Canada. Ottawa: CCOHTA, 1994.Google Scholar
8.Caro, J. J., Trindade, E., & McGregor, M.The cost-effectiveness of replacing highosmolality with low-osmolality contrast media. American Journal of Roentgenology, 1992, 159, 869–74.Google Scholar
9.Churchill, D. N., Lemon, B. C., & Torrance, G. W.A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Medical Decision Making, 1984, 4, 489–500.Google Scholar
10.Coy, P., Schaafsma, J., Schofield, J. A., & Nield, J. A.Comparative costs of lung cancer management. Clinical and Investigative Medicine, 1994, 17, 577–87.Google Scholar
11.Detsky, A. S., & Jeejeebhoy, K. N.Cost-effectiveness of preoperative parenteral nutrition in patients undergoing major gastrointestinal surgery. Journal of Parenteral and Entera Nutrition, 1984, 8, 632–37.Google Scholar
12.Donaldson, C.The state of the art of costing health care for economic evaluation. Community Health Studies, 1990, 14, 341–56.Google Scholar
13.Drummond, M. F., Stoddart, G. L., & Torrance, G. W.Methods for the economic evaluation of health care programs. Oxford: Oxford Medical Publications, 1987.Google Scholar
14.Eddy, R. J.Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer. Canadian Association of Radiologists Journal, 1989, 40, 189–93.Google Scholar
15.Einarson, T. R., Arikian, S. R., & Shear, N. H.Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. British Journal of Dermatology, 1994, 130, S32–34.Google Scholar
16.Ellis, E., Koblin, W., Irvine, M. J., et al. Small, blue collar work site hypertension screening: A cost-effectiveness study. Journal of Occupational Medicine, 1994, 36, 346–55.Google Scholar
17.Estany, A.,Todd, M., Vasquez, M., & McLaren, R.Early detection of genital chlamydial infection in women: An economic evaluation. Sexually Transmitted Diseases, 1989, 16, 21–27.CrossRefGoogle ScholarPubMed
18.Evans, R. G., & Robinson, G. C.Surgical day care: Measurements of the economic payoff. Canadian Medical Association Journal, 1980, 123, 873–80.Google Scholar
19.Ferris, F. D., Wodinsky, H. B., Kerr, I. G., et al. A cost-minimization study of cancer patients requiring a narcotic infusion in hospital and at home. Journal of Clinical Epidemiology, 1991, 44, 313–27.CrossRefGoogle ScholarPubMed
20.Fitzgerald, J. M., & Gafni, A.A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. American Review of Respiratory Disease, 1990, 142, 848–53.Google Scholar
21.Fulton, M. J., & Barer, M. L.Screening for congenital dislocation of the hip: An economic appraisal. Canadian Medical Association Journal, 1984, 130, 1149–56.Google ScholarPubMed
22.Gabriel, S. E., Jaakkimainen, R. L., & Bombardier, C.The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis and Rheumatism, 1993, 36, 447–59.Google Scholar
23.Gerson, L. W., & Hughes, O. P.A comparative study of the economics of home care. International Journal of Health Services, 1976, 6, 543–55.Google Scholar
24.Goel, V., Deber, R. B., & Detsky, A. S.Nonionic contrast media: Economic analysis and health policy development. Canadian Medical Association Journal, 1989, 140, 389–95.Google ScholarPubMed
25.Goel, V., & Naylor, C. D.Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Canadian Journal of Cardiology, 1992, 8, 31–38.Google Scholar
26.Goodwin, P. J., Feld, R., Evans, W. K., & Pater, J.Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. Journal of Clinical Oncology, 1988, 6, 1537–47.Google Scholar
27.Grizenko, N., & Papineau, D.A comparison of the cost-effectiveness of day treatment and residential treatment for children with severe behaviour problems. Canadian Journal of Psychiatry, 1992, 37, 393–400.Google Scholar
28.Gyldmark, M.A review of cost studies of intensive care units: Problems with the cost concept. Critical Care Medicine, 1995, 23, 964–72.Google Scholar
29.Hamilton, V. H., Racicot, F. E., Zowall, H., et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. Journal of the American Medical Association, 1995, 273, 1032–38.Google Scholar
30.Hull, R., Hirsh, J., Sackett, D. L., & Stoddart, G.Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. New England Journal of Medicine, 1981, 304, 1561–67.Google Scholar
31.Hull, R. D., Hirsh, J., Sackett, D. L., & Stoddart, G. L.Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Canadian Medical Association Journal, 1982, 127, 990–95.Google Scholar
32.Hull, R. D., Raskob, G. E., Hirsh, J., & Sackett, D. L.A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. Journal of the American Medical Association, 1984, 252, 235–39.Google Scholar
33.Hutchison, B. G., & Stoddart, G. L.Cost-effectiveness of primary tetanus vaccination among elderly Canadians. Canadian Medical Association Journal, 1988, 139, 1143–51.Google Scholar
34.Jaakkimainen, L., Goodwin, P. J., Pater, J., et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. Journal of Clinical Oncology, 1990, 8, 1301–09.Google Scholar
35.Jacobs, P., Henderson, I., & Nichols, D.Episodic acute care costs: Linking inpatient and home care. Canadian Journal of Public Health, 1995, 86, 200–05.Google Scholar
36.Kitai, I. C., King, S., & Gafni, A.An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients. Clinical Infectious Diseases, 1993, 17, 441–47.Google Scholar
37.Krahn, M., & Detsky, A. S.Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Medical Decision Making, 1993, 13, 4–20.CrossRefGoogle ScholarPubMed
38.Kukull, W. A., Koepsell, T. D., Conrad, D., et al. Rapid estimation of hospitalization charges from a brief medical record review. Medical Care, 1986, 24, 961–66.Google Scholar
39.Labelle, R. J., Churchill, D. N., Martin, S., et al. Economic evaluation of extracorporeal shock wave lithotripsy, percutaneous ultrasonic lithotripsy, and standard surgical treatment of urolithiasis: A Canadian perspective. Clinical and Investigative Medicine, 1987, 10, 86–95.Google Scholar
40.Laupacis, A., Labelle, R., Goeree, R., & Cairns, J.The cost-effectiveness of routine post myocardial infarction exercise stress testing. Canadian Journal of Cardiology, 1990, 6, 157–63.Google Scholar
41.Levine, M. N., Drummond, M. F., & Labelle, R. J.Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin. Canadian Medical Association Journal, 1985, 133, 977–87.Google Scholar
42.Logan, A. G., Milne, B. J., Achber, C., et al. Cost-effectiveness of a worksite hypertension treatment program. Hypertension, 1981, 3, 211–18.Google Scholar
43.Logan, A. G., Milne, B. J., Flanagan, P. T., & Haynes, R. B.Clinical effectiveness and cost-effectiveness of monitoring blood pressure of hypertensive employees at work. Hypertension, 1983, 5, 828–36.Google Scholar
44.McEwan, A. J. B., Amyotte, G. A., McGowan, D. G., et al. A retrospective analysis of the cost effectiveness of treatment with metastron in patients with prostate cancer metastatic to bone. European Urology, 1994, 26(Suppl. 1), 26–31.Google Scholar
45.Musto, R. J.Cost-effectiveness analysis of endocervical culture for N. gonorrhoeae at routine pelvic examination. Canadian Journal of Public Health, 1986, 77, 33–36.Google ScholarPubMed
47.Oldridge, N., Furlong, W., Feeny, D., et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. American Journal of Cardiology, 1993, 72, 154–61.CrossRefGoogle ScholarPubMed
48.Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994.Google Scholar
50.Pineault, R., Contandriopoulos, A. P., Valois, M., et al. Randomized clinical trial of one-day surgery: Patient satisfaction, clinical outcomes, and costs. Medical Care, 1985, 23, 171–82.Google Scholar
46.O'Brien, B. J., Anderson, D. R., & Goeree, R.Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Canadian Medical Association Journal, 1994, 150, 1083–90.Google Scholar
49.Ostrowsky, J. T., Lippman, A., & Scriver, C. R.Cost-benefit analysis of a thalassemia disease prevention program. American Journal of Public Health, 1985, 75, 732–36.CrossRefGoogle ScholarPubMed
51.Rajan, R., Gafni, A., Levine, M., et al. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: An economic evaluation. Journal of Clinical Oncology, 1995, 13, 41–46.Google Scholar
52.Scriver, C. R., Gregory, D., Bernstein, M., et al. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec. Canadian Medical Association Journal, 1987, 136, 952–56.Google Scholar
53.Sellors, J. W., Pickard, L., Gafni, A., et al. Effectiveness and efficiency of selective vs universal screening for chlamydial infection in sexually active young women. Archives of Internal Medicine, 1992, 152, 1837–44.Google Scholar
54.Sheingold, S., Churchill, D., Muirhead, N., et al. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Social Science and Medicine, 1992, 34, 983–91.Google Scholar
55.Tolley, K. & Glydmark, M.The treatment and care costs of people with HIV infections or AIDS: Development of a standardised cost framework for Europe. Health Policy, 1993, 24, 55–70.Google Scholar
56.Tousignant, P., Guttmann, R. D., & Hollomby, D. J.Transplantation and home hemodialysis: Their cost-effectiveness. Journal of Chronic Diseases, 1985, 38, 589–601.Google Scholar
57.Welch, H. G., & Larson, E. B.Rapid estimation of hospital charges in patients with leukemia. Medical Care, 1989, 27, 900–04.Google Scholar
58.Whynes, D. K. & Walker, A. R.On approximations in treatment costing. Health Economics, 1995, 4, 31–39.Google Scholar
59.Zowall, H., Fraser, R. D., Gilmore, N., et al. HIV antibody screening among immigrants: A cost-benefit analysis. Canadian Medical Association Journal, 1990, 143, 101–07.Google Scholar